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INTRODUCTION
Since its initial description in 1965 (1), carcinoembryonic
antigen (CEA) has remained the most thoroughly investigat-
ed tumor marker. CEA is an intracellular protein normally
found in low concentrations in embryonic and fetal gut, pan-
creas, and liver cells, as well as in several adult tissues. It may
be elevated in smokers and in several malignant and benign
conditions of the gastrointestinal tract (2). CEA expressed
in large quantities in approximately 95% of colorectal carci-
nomas, and the relationship between serum CEA (s-CEA)
level and colorectal cancer has been studied extensively. It has
been shown that preoperative s-CEA levels increases with
tumor stage (3), and elevated preoperative s-CEA levels have
been found to predict a higher incidence of recurrence (4) in
patients with colorectal cancer. In addition, the relationship
between preoperative s-CEA level and survival has suggest-
ed a predictive value of the former for metastasis or recurrence
in colorectal cancer patients (5, 6). At present, s-CEA is mea-
sured primarily during follow-up of colorectal cancer patients,
so that patients with high s-CEA levels receive more inten-
sive treatment (7). 
The prognostic value of preoperative s-CEA has been stud-
ied, but no practical cutoff value has been determined. We
therefore tried to reassess whether preoperative s-CEA level
can be used as a prognostic factor in colorectal cancer patients.
In addition, we sought to determine the cutoff values of s-CEA
for predicting outcome.
MATERIALS AND METHODS
One thousand eighty-three patients had curative resections
for stages I, II, and III colorectal cancer at Asan Medical Cen-
ter between July 1990 and December 1997. Patients in whom
preoperative s-CEA level was measured were considered eli-
gible for the study. Patients initially presenting with metastatic
disease and those who underwent palliative resection were
excluded, leaving a total of 989 patients. Their mean age was
57 yr (range, 21-89 yr); 527 were males, and 462 were females.
Median follow-up was 46 months (range, 3-129 months).
Of the 989 patients, 164 (16.6%) had stage I, 374 (37.8%)
had stage II, and 451 (46%) had stage III tumors. 
Serum CEA was measured by enzyme immunoassay (ELISA-
2-CEA kit�; CIS Biointernational, Marcule, France). The nor-
mal range of s-CEA in our laboratory was set as <6 ng/mL, as
determined by measurements in 313 Korean healthy persons
using the same kit. The s-CEA levels varied between 0.1 and
6.4 ng/mL, with a mean (±S.D.) of 2.25±1.25 ng/mL (8).
To determine the s-CEA cutoff values that may discrimi-
nate between patients with good and those with poor prog-
nosis, we performed a multi-step analysis of survival curve.
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Cutoff Values of Preoperative s-CEA Levels for Predicting Survivals
after Curative Resection of Colorectal Cancer
Serum carcinoembryonic antigen (s-CEA) is used to detect recurrence and predict
prognosis in colorectal cancer. However, the cutoff values of s-CEA for prognosis
have not been determined. We therefore tried to determine the preoperative s-
CEA levels predictive of survivals in colorectal cancer patients. We retrospectively
analyzed the medical records of 989 patients who underwent curative resection
for colorectal cancer between July 1990 and December 1997, with a mean follow-
up of 46 months (range, 3-129 months). When patients were divided into four sub-
groups with the cutoff values of s-CEA at 3,6, and 17 ng/mL, their 5-yr disease-
free survival rates were 85.3% (<3.0 ng/mL), 70.0% (3-6 ng/mL), 64.2% (6-17
ng/mL), and 55.2% (>17 ng/mL) (p<0.001). Multivariate analysis showed that fac-
tors predictive of survival included age (p=0.028), tumor stage (p<0.001), cell dif-
ferentiation (p=0.016), and gross type (p=0.007), location (p=0.003) and preopera-
tive s-CEA (p<0.001). Using the above-described cutoff levels, a significant differ-
ence in survival was observed only in patients with stage III tumors (p=0.007)
when analyses were performed by stage. We can suggest the new cutoff values
of s-CEA used in the present study.
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First, we constructed survival curves according to their pre-
operative CEA levels, and compared them. Then, we con-
structed survival curves for patients with levels beginning
from 1 ng/mL and increasing by 1 ng/mL increments, and
we compared the curves for each s-CEA level independently.
If we found several levels, which showed different survivals,
they were compared after the group was divided according
to all level. We repeated these steps for levels showing a dif-
ference in survival. We chose cutoff levels that most clearly
divided patients into subgroups with regard to survival rate
by the Kaplan-Meier method with a log rank test. Multi-
variate analysis was calculated by the Cox proportional haz-
ard model. Statistical significance was defined as p<0.05.
RESULTS
When we set the cutoff values of s-CEA at 3, 6, and 17
ng/mL, the patients were divided into four subgroups with
significantly different 5-yr disease-free survival rates (p<0.001).
Of the 989 patients, 288 (29.1%) had s-CEA below 3 ng/mL,
401 (40.5%) had s-CEA of 3-6 ng/mL, 176 (17.8%) had s-
CEA of 6-17 ng/mL, and 124 (12.5%) had s-CEA over 17
ng/mL. The survival rates in these four subgroups were 85.3%,
70.0%, 64.2%, and 55.2%, respectively (Fig. 1). The four
subgroups did not differ significantly with respect to age,
sex, location of primary tumor or cellular differentiation. We
found, however, that, as s-CEA level increased, the gross pat-
tern of diffuse type (p=0.007) and stage III (p<0.001) also
increased (Table 1). 
Mean preoperative s-CEA levels with respect to AJCC
stage were 4.01 ng/mL (range, 1.0-37.5 ng/mL) in stage I,
11.07 ng/mL (range, 0.7-556.0 ng/mL) in stage II and 23.10
ng/mL (rage, 0.7-2510.0 ng/mL) in stage III, but these dif-
ferences did not achieve statistical significance (p=0.07). When
we determined s-CEA levels relative to T and N categories,
we found that mean s-CEA level increased progressively by
N category (p<0.001), but there was no correlation between
mean s-CEA level and T category. 
Using the above-described cutoff levels, a significant dif-
s-CEA (ng/mL)
p
≤2.9 3-5.9 6-16.9 ≥17.0
Overall 288 401 176 124
Age (yr) 0.06
≤40 45 (15.6) 48 (12.0) 17 (9.7) 20 (16.1)
40-60 148 (51.4) 180 (44.9) 76 (43.2) 57 (46.0)
>60 95 (33.0) 173 (43.1) 83 (47.1) 47 (37.9)
Sex 0.18
Male 147 (51.0) 227 (56.6) 84 (47.7) 69 (55.6)
Female 141 (49.0) 174 (43.4) 92 (52.3) 55 (44.4)
Location 0.208
Colon 137 (47.6) 174 (43.4) 72 (40.9) 64 (51.6)
Rectum 151 (52.4) 227 (56.6) 104 (59.1) 60 (48.4)
Gross type 0.001
Fungating 70 (24.3) 82 (20.4) 23 (13.1) 10 (8.1)
Fungating+diffuse 192 (66.7) 260 (64.8) 26 (14.7) 94 (75.8)
Diffuse 26 (9.0) 59 (14.8) 26 (14.7) 20 (16.1)
Differentiation 0.197
Well, moderately 252 (87.5) 355 (88.5) 156 (88.6)101 (81.5)
differentiated
Poorly differen- 36 (12.5) 46 (11.5) 20 (11.4) 23 (18.5)
tiated, mucinous
� Stage <0.001
I 71 (24.7) 74 (18.5) 17 (9.7) 2 (1.6)
II 109 (37.8) 154 (38.4) 70 (39.8) 41 (33.1)
III 108 (37.5) 173 (43.1) 89 (50.6) 81 (65.3)
*No in parentheses are %, 
� AJCC 6th edition.
Table 1. Clinicopathological characteristics of patients with respect
to s-CEA concentration
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Fig. 1. Disease-free survival curves of colorectal cancer patients
relative to preoperative s-CEA levels. Survival is significantly relat-
ed to preoperative s-CEA levels.
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Fig. 2. Preoperative s-CEA levels and disease-free survival rate
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ference in survival was observed only in patients with stage
III tumors (p=0.007), not in those with stages I and II (Fig.
2). By multivariate analysis, preoperative s-CEA level using
these new cutoff values was an independent prognostic factor
of survival (p<0.001), as were age (p=0.028), tumor stage (p<
0.001), differentiation (p=0.016), and gross type (p=0.007),
location (p=0.003) and preoperative s-CEA (p<0.001) (Table 2).
DISCUSSION
Since its first description, the clinical importance of s-CEA
in the management of colorectal cancer patients has been
investigated extensively, and it has been reported to predict
recurrence or metastasis of this disease (3-6, 9-11). There were
several drawbacks to these previous studies, however, includ-
ing the use of arbitrary cutoff levels. In most studies, survival
and recurrence rates were compared between patients with
normal s-CEA level and those with elevated s-CEA (9-11),
but these groups were not further stratified. In addition, the
normal level of s-CEA was set arbitrarily, leading to insuffi-
cient determination of the prognostic function of s-CEA level.
To correct these possible errors, we stratified s-CEA levels by
comparing survival curves of patients below and above each
s-CEA level, starting at 1 ng/mL and increasing by increments
of 1 ng/mL. 
We selected 3, 6, and 17 ng/mL s-CEA as practical cutoff
points, which highly discriminate between higher and lower
risk groups with respect to survival. In contrast, our evalua-
tion did not attribute any discriminatory function to any other
s-CEA level. It is interesting result considering we did not
consider the importance of serum CEA, which confined with-
in the normal range usually. Thus, regardless of pathologic
stage, these patients could be stratified into subgroups with
different prognoses based on their preoperative s-CEA levels,
with patients having the highest preoperative s-CEA levels
(i.e., >17 ng/mL) having the highest risk of metastasis or recur-
rence.
CEA is expressed throughout life in normal adult tissues,
including the colon, stomach, tongue, cervix, and prostate
(1, 12). In the normal colon, CEA may be associated with
cellular differentiation, and the degree of expression may be
related to differentiation status (13). In colon cancer, CEA
appears to provide a variety of cellular functions, including
adhesion, in both intracellular and CEA-matrix interactions
(14-17), signal transduction, and cellular migration (18-20),
suggesting that CEA has a role as a facilitator of tumor inva-
sion and metastasis. On the molecular level, there appears
to be no difference between normal colonic CEA and tumor
CEA, although the possibility that subtle posttranslational
modifications may create differences cannot be excluded (13).
Our clinical data suggest that CEA may act in a dose-depen-
dent manner. Thus, enhanced expression of CEA may confer
on cancer cells the ability to invade adjacent tissues and to
metastasize to lymph nodes or distant organs. Even normal
serum levels of CEA may enhance cancer cell invasiveness,
giving rise to more aggressive tumor cells.  
Tumor stage is the most important predictor of survival in
colorectal cancer (5, 6), and s-CEA levels tended to increase
progressively with the stage of disease (3). In the present study,
preoperative s-CEA level could be correlated with survival
only in patients with stage III tumors, not those with stages
I and II. This result conflicts with an earlier report (4), in
which disease-free survival of patients with Dukes B and C
lesions was related to preoperative s-CEA level. Our finding,
however, is in agreement with a study showing no such cor-
relation in patients with Dukes B lesions (21). It is not clear
whether these differences are due to selection factors, differ-
ent pathologic staging, small sample sizes, or a combination
of these factors. Moreover, when we attempted to coordinate
T and N categories of AJCC stage with preoperative s-CEA
levels, we found that N, but not T, category was correlated
with s-CEA, suggesting a connection of the latter with nodal
metastasis. 
Our findings suggest that preoperative s-CEA levels could
be used as a stratification parameter for identifying subsets of
colorectal cancer patients with different prognoses. Especially,
patients with preoperative s-CEA above 3.0 ng/mL should
be considered at higher risk compared with those with below
3.0 ng/mL, although this value is within the normal range,
95% confidence
interval
Variables Odds ratios p
Sex 0.069
Female 0.787 0.608-1.019
Male 1
Age (yr) 0.028
>60 1.457 0.956-2.220
40-60 1.173 0.776-1.775
≤40 1
s-CEA (ng/mL) <0.001
≥17 2.654 1.720-4.094
6-16.9 1.913 1.251-2.926
3-5.9 1.722 1.185-2.502
<3 1
Gross type 0.007
Diffuse 2.133 1.253-3.630
Fungating , diffuse 1.581 0.986-2.533
Fungating 1
Differentiation 0.016
Poorly differentiated, mucinous  1.578 1.135-2.193
Well, moderately differentiated 1
Location 0.003
Rectum 1.496 1.143-1.958
Colon 1
Stage <0.001
III 7.249 3.343-15.720
II 2.705 1.209-6.051
I1
Table 2. Factors related to survival rate: Multivariate analysis using
Cox’s hazard models-CEA as a Prognostic Factor 627
especially in patients with stage III tumors. In addition, a
prospective study is needed to determine the clinical useful-
ness of these cut-off values. 
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